Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner

Hepatology

Volumn 56, Issue 1, 2012, Pages 49-56

  Clark, Paul J ^a,b   Thompson, Alexander J ^a   Vock, David M ^a   Kratz, Lisa E ^c   Tolun, Adviye A ^a   Muir, Andrew J ^a   Mchutchison, John G ^a   Subramanian, Mani ^d   Millington, David M ^a   Kelley, Richard I ^c   Patel, Keyur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; CHOLESTEROL; LANOSTEROL; RIBAVIRIN; VIRUS RNA;

ARTICLE; BODY MASS; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; FATTY LIVER; GAS CHROMATOGRAPHY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ALBUMINS; ANTIVIRAL AGENTS; CHOLESTEROL; CHROMATOGRAPHY, GAS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LANOSTEROL; LIPID METABOLISM; MALE; MASS SPECTROMETRY; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; PROGNOSIS; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84863524541     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25631     Document Type: Article

References (38)

1. Jones DM, McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J Biol Chem 2010; 285: 22733-22739.
2. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, et al. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med 2010; 16: 277-286.
3. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59: 1279-1287.
4. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY 1999; 29: 1215-1219.
5. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-f, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001; 33: 1358-1364.
6. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
7. Harrison SA, Elizabeth MB, Rizwan AQ, Dana AO, Brent ANT, Adrian MDB, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 604-609.
8. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. HEPATOLOGY 2010; 52: 864-874.
9. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. HEPATOLOGY 2009; 50: 1030-1037.
10. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-881.
11. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. HEPATOLOGY 1999; 29: 328-333.
12. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423.
13. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. HEPATOLOGY 2007; 45: 1164-1171.
14. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102: 2561-2566.
15. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007; 81: 8122-8130.
16. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46: 411-419.
17. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99: 15669-15674.
18. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-2129.
19. Vidali M, Tripodi M-F, Ivaldi A, Zampino R, Occhino G, Restivo L, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008; 48: 399-406.
20. Kelley RI. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin Chim Acta 1995; 236: 45-58.
21. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 1994; 330: 107-113.
22. Lin S, Liu N, Yang Z, Song W, Wang P, Chen H, et al. GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus. Talanta 2010; 83: 262-268.
23. Fitzky BU, Moebius FF, Asaoka H, Waage-Baudet H, Xu L, Xu G, et al. 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest 2001; 108: 905-915.
24. Roitelman J, Simoni RD. Distinct sterol and nonsterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem 1992; 267: 25264-25273.
25. Marijanovic Z, Laubner D, Moller G, Gege C, Husen B, Adamski J, et al. Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol Endocrinol 2003; 17: 1715-1725.
26. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
27. Bain VG, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ, et al. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008; 6: 701-706.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
29. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988; 75: 383-386.
30. Waterham HR, Koster J, Romeijn GJ, Hennekam RCM, Vreken P, Andersson HC, et al. Mutations in the 3β-hydroxysterol Δ24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001; 69: 685-694.
31. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115.
32. Lee JN, Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J Biol Chem 2004; 279: 45257-45265.
33. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MMC, Ou J-h. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. HEPATOLOGY 2004; 39: 81-89.
34. Song B-L, Javitt NB, DeBose-Boyd RA. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab 2005; 1: 179-189.
35. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
36. Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A 2010; 107: 291-296.
37. Owens CM, Mawhinney C, Grenier JM, Altmeyer R, Lee MS, Borisy AA, et al. Chemical combinations elucidate pathway interactions and regulation relevant to hepatitis C replication. Mol Syst Biol 2010; 6.
38. Ye J, Wang C, Sumpter R, Brown MS, Goldstein JL, Gale M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100: 15865-15870.